scholarly article | Q13442814 |
P2093 | author name string | B K Park | |
S Madden | |||
T F Woolf | |||
V Spaldin | |||
W F Pool | |||
P2860 | cites work | Protein measurement with the Folin phenol reagent | Q20900776 |
Enoxacin raises plasma theophylline concentrations | Q28261528 | ||
Metabolic oxidation and toxification of N-methylformamide catalyzed by the cytochrome P450 isoenzyme CYP2E1 | Q28319041 | ||
THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE | Q29547810 | ||
Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors | Q34420999 | ||
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies | Q34447046 | ||
Inhibitory effects of neuroleptics on debrisoquine oxidation in man | Q34447792 | ||
The influence of quinolone derivatives on theophylline clearance | Q34448229 | ||
The effects of cimetidine on the oxidative metabolism of estradiol | Q34535925 | ||
Danger of interaction between ciprofloxacin and theophylline | Q36895731 | ||
Clinical experience with and side-effects of tacrine hydrochloride in Alzheimer's disease: a pilot study | Q38719669 | ||
Pharmacokinetic interactions of cimetidine 1987. | Q39662361 | ||
In vitro approaches can predict human drug metabolism | Q40784165 | ||
In vitro methods for assessing human hepatic drug metabolism: their use in drug development | Q40817420 | ||
Cimetidine-carbaryl interaction in humans: evidence for an active metabolite of carbaryl | Q41111368 | ||
In vitro effects of quinoline derivatives on cytochrome P-450 and aminopyrine N-demethylase activity in rat hepatic microsomes | Q41918372 | ||
Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. | Q41921824 | ||
Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs | Q41944104 | ||
The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. | Q42284991 | ||
The effect of preincubation with cimetidine on the N-hydroxylation of dapsone by human liver microsomes | Q43205011 | ||
Metabolism of ciamexon by human liver microsomes: an investigation into the formation of stable, chemically reactive and cytotoxic metabolites | Q43222882 | ||
Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. | Q43411735 | ||
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group | Q44110810 | ||
Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease | Q44223667 | ||
Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. | Q51671371 | ||
Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. | Q52259713 | ||
Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. | Q52401805 | ||
Tacrine in Alzheimer's disease | Q56763713 | ||
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease | Q67516972 | ||
Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes | Q68168251 | ||
Metabolism of the contraceptive steroid desogestrel by human liver in vitro | Q68411414 | ||
Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide | Q68411894 | ||
Decrease of caffeine elimination in man during co-administration of 4-quinolones | Q68781944 | ||
Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients | Q69375733 | ||
Evidence for induction of hepatic microsomal cytochrome P-450 by cimetidine: binding and kinetic studies | Q70291786 | ||
Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism | Q71259532 | ||
Interaction of cimetidine with cytochrome P450 and effect on mixed-function oxidase activities of liver microsomes | Q72215172 | ||
Quinolones and raised plasma concentrations of theophylline | Q72586826 | ||
Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference | Q72658526 | ||
An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes | Q72870562 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 15-22 | |
P577 | publication date | 1994-07-01 | |
P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
P1476 | title | The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes | |
P478 | volume | 38 |
Q35802571 | Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease |
Q73647451 | Characterization of the induction of rat microsomal cytochrome P450 by tacrine |
Q40472033 | Clinical Pharmacokinetics of Tacrine |
Q46675103 | Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo |
Q47651680 | Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy. |
Q36061821 | Drug bioactivation, covalent binding to target proteins and toxicity relevance |
Q78019948 | Effect of tacrine hydrochloride on hepatic drug metabolism |
Q41334623 | Human P450 metabolism of warfarin |
Q41172369 | Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism |
Q46986336 | In-vitro stability and metabolism of a tacrine-silibinin codrug |
Q34741428 | Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans* |
Q34732916 | Inhibition of tacrine oral clearance by cimetidine |
Q89603158 | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology |
Q24791908 | NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant |
Q34994964 | New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme |
Q41128196 | Noninterference of cytochrome P4501A2 in the cytotoxicity of tacrine using genetically engineered V79 Chinese hamster cells for stable expression of the human or rat isoform and two human hepatocyte cell lines |
Q37611786 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. |
Q43244977 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. |
Q36179528 | Role of metabolism in drug-induced idiosyncratic hepatotoxicity |
Q71856356 | Species variation in the bioactivation of tacrine by hepatic microsomes |
Q35015993 | Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. |
Q32103802 | Summary of information on human CYP enzymes: human P450 metabolism data |
Q48760407 | Tacrine and its analogues impair mitochondrial function and bioenergetics: a lipidomic analysis in rat brain. |
Q73567801 | The effect of velnacrine on the mixed function oxidase system |
Q41401684 | The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition |
Q38561490 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases |
Q34617272 | Tribuli fructus constituents protect against tacrine-induced cytotoxicity in HepG2 cells |
Q36851934 | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions |